Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia
Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia
复制标题
NSC606985（一种新型喜树碱类似物）在急性早幼粒细胞白血病小鼠模型中的治疗效果。
DOI：
10.1016/j.leukres.2007.03.011
复制
发表时间：
2007-11-01
影响因子：
2.7
通讯作者：
Chen, Guo-Qiang
中科院分区：
文献类型：
--
作者：
Wei, Liu;Zhu, Yuan-Shan;Chen, Guo-Qiang
纳米浓度的NSC606985是一种新型喜树碱（CPT）类似物，在体外有效诱导急性髓性白血病（AML）细胞凋亡。在这里，我们研究了NSC606985对急性早幼粒细胞白血病（APL）小鼠模型的潜在治疗作用，APL是AML的一种独特亚型。结果表明，单剂量NSC606985能迅速消除外周血和组织中白血病细胞的浸润，诱导白血病细胞凋亡。NSC606985采用连续单药治疗和间歇长期治疗两种方案治疗，可显著延长白血病小鼠肿瘤消退的生存期。这些结果表明，NSC606985值得进一步的临床前和临床研究来治疗AML。(c) 2007 Elsevier Ltd.版权所有。
Nanomolar concentrations of NSC606985, a novel camptothecin (CPT) analog, effectively induces apoptosis in vitro in acute myeloid leukemic (AML) cells. Here we investigated the potential therapeutic effects of NSC606985 on the mice model with acute promyelocytic leukaemia (APL), a unique subtype of AML. The results showed that NSC606985 at single dose rapidly eliminated the infiltration with apoptois induction of leukemic cells in peripheral blood and tissues. Treatment of NSC606985 with two regimens, continuous monotherapy and intermittent long-term therapy, significantly prolonged the survival of leukemic mice with tumor regression. These results propose that NSC606985 warrants further preclinical and clinical investigations for AML treatment. (c) 2007 Elsevier Ltd. All rights reserved.